Blair William & CO Regeneron Pharmaceuticals, Inc. Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Blair William & CO holds 2,043 shares of REGN stock, worth $1.54 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,043

Previous 1,985 2.92%

Holding current value

$1.54 Million

Previous $2.09 Million 2.92%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1024.09 - $1201.76 $59,397 - $69,702	58 Added 2.92%	2,043 $2.15 Million
Q2 2024 Aug 12, 2024	SELL	$883.2 - $1071.19 $34,444 - $41,776	-39 Reduced 1.93%	1,985 $2.09 Million
Q1 2024 May 09, 2024	BUY	$902.69 - $993.35 $7,221 - $7,946	8 Added 0.4%	2,024 $1.95 Million
Q4 2023 Feb 12, 2024	BUY	$775.18 - $881.7 $353,482 - $402,055	456 Added 29.23%	2,016 $1.77 Million
Q3 2023 Nov 09, 2023	SELL	$692.45 - $844.37 $155,801 - $189,983	-225 Reduced 12.61%	1,560 $1.28 Million
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $128,105 - $151,954	-183 Reduced 9.3%	1,785 $1.28 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $281,042 - $341,538	-413 Reduced 17.35%	1,968 $1.62 Million
Q4 2022 Feb 10, 2023	BUY	$705.89 - $766.39 $799,773 - $868,319	1,133 Added 90.79%	2,381 $1.72 Million
Q3 2022 Nov 09, 2022	BUY	$573.97 - $724.32 $69,450 - $87,642	121 Added 10.74%	1,248 $860,000
Q2 2022 Aug 10, 2022	SELL	$548.35 - $738.84 $166,698 - $224,607	-304 Reduced 21.24%	1,127 $666,000
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $132,116 - $155,051	222 Added 18.36%	1,431 $999,000
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $274,457 - $338,839	-505 Reduced 29.46%	1,209 $764,000
Q3 2021 Nov 12, 2021	SELL	$574.03 - $680.96 $73,475 - $87,162	-128 Reduced 6.95%	1,714 $1.04 Million
Q2 2021 Aug 12, 2021	BUY	$472.8 - $558.54 $27,895 - $32,953	59 Added 3.31%	1,842 $1.03 Million
Q1 2021 May 13, 2021	BUY	$446.73 - $548.2 $237,660 - $291,642	532 Added 42.53%	1,783 $844,000
Q4 2020 Feb 09, 2021	SELL	$478.3 - $607.98 $129,141 - $164,154	-270 Reduced 17.75%	1,251 $604,000
Q3 2020 Nov 06, 2020	BUY	$544.75 - $658.21 $94,241 - $113,870	173 Added 12.83%	1,521 $851,000
Q2 2020 Aug 12, 2020	BUY	$493.32 - $643.92 $68,078 - $88,860	138 Added 11.4%	1,348 $841,000
Q1 2020 May 11, 2020	BUY	$336.18 - $494.43 $34,962 - $51,420	104 Added 9.4%	1,210 $591,000
Q4 2019 Feb 13, 2020	SELL	$274.13 - $376.51 $100,605 - $138,179	-367 Reduced 24.92%	1,106 $415,000
Q3 2019 Nov 12, 2019	SELL	$273.46 - $318.39 $50,316 - $58,583	-184 Reduced 11.1%	1,473 $409,000
Q2 2019 Aug 13, 2019	BUY	$299.6 - $414.82 $14,980 - $20,741	50 Added 3.11%	1,657 $519,000
Q1 2019 May 14, 2019	BUY	$372.08 - $439.57 $160,738 - $189,894	432 Added 36.77%	1,607 $660,000
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $6,716 - $8,060	20 Added 1.73%	1,175 $439,000
Q2 2018 Aug 13, 2018	SELL	$284.6 - $344.99 $232,802 - $282,201	-818 Reduced 41.46%	1,155 $398,000
Q1 2018 May 15, 2018	SELL	$315.82 - $393.78 $2,842 - $3,544	-9 Reduced 0.45%	1,973 $679,000
Q4 2017 Feb 14, 2018	BUY	$358.63 - $469.95 $50,925 - $66,732	142 Added 7.72%	1,982 $745,000
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $793,739 - $927,360	1,840	1,840 $823,000

Others Institutions Holding REGN

# of Institutions

1,532

Shares Held

83.8M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $80.9B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account